Nerve inflammation by own immune system periferal motor neuropathy
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Multifocal Motor Neuropathy
Exclusion criteria
Exclusion criteria: No Multifocal motor neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - the Overall Disability Sum Score (ODSS) ranging from 0 (normal) to 5 for the arms and to 7 for the legs and Rankin scores; - the Fatigue Severity Scale (FSS) scores; - Medical Research Council (MRC) sum scores or myometric scores; - Time needed to perform the 9-hole peg test; compared to the data obtained in 2007. -SF-36 domain scores and physical and mental component scores will be used to document QoL. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Carriership rates of H. Influenzae and the presence of GM1 like stuctures on bacteria. - We will look for nerve and brachial plexus abnormalities on T1W and STIR (T2W) MR images, in particular for thickening and increased T2W signal that probably reflects, inflammation and compare MMN and MND patients and healthy controls. We will also compare EMG findings in MMN patients with MRI findings to investigate whether we can image the CB. -HRUS will be performed in all MMN patients and in the MND patients who undergo MRI of the forearm. HRUS results will be compared to EMG and MRI in the MMN subgroup who underwent all three investigations. Finally, HRUS results will be studied in relation to patient characteristics (i.e. weakness, disability, response to treatment, presence of axonal damage). A subgroup of patients has had US in the past21 to see if HRUS is a biomarker for disease progression the 21 patients who were included will be asked again for HRUS. -Changes in IVIg concentration before and after treatment and over time in patients who are IVIg naïve and start IVIG maintenance treatment. Next to this parameter, HRUS findings over time (one year) are measured to test its value as a prognostic biomarker for clinical decline and/or response to IVIg. - Nerve excitability in MMN patients as a pilot study and compare results to former data of excitability on healthy controls. Results include strength duration time constant, threshold electrotonus, recovery cycle and will be compared with the already available data in healthy persons. | — |
Countries
Netherlands
Outcome results
None listed